daunorubicin + transforming growth factor beta + Epstein-Barr virus-specific T cells

This experimental combination therapy consists of the anthracycline chemotherapy agent daunorubicin and Epstein-Barr virus-specific T cells (EBV-VSTs) that are typically engineered to be resistant to the immunosuppressive effects of transforming growth factor beta (TGF-beta). Daunorubicin is a small molecule topoisomerase II inhibitor and DNA intercalator used primarily in the treatment of acute leukemias. The EBV-VSTs are an adoptive cell therapy designed to recognize and eliminate cells expressing Epstein-Barr virus antigens, such as LMP1 and LMP2, which are prevalent in EBV-associated malignancies. To enhance their efficacy within the immunosuppressive tumor microenvironment, these T cells are often genetically modified to express a dominant-negative TGF-beta receptor (DNRII). This modification prevents endogenous TGF-beta from signaling through the T cells' native receptors, thereby protecting them from TGF-beta-mediated inhibition of proliferation and cytotoxicity. This combination is investigated for EBV-positive hematologic cancers, including certain lymphomas and leukemias where daunorubicin is a standard component of induction or salvage chemotherapy.

Other names

daunorubicin + TGF-beta resistant EBV-VSTsdaunorubicin + DNRII-EBV-VSTs